RMD insider transactions

Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)

Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)

SEC Form 3 filed by new insider Bloomer Aaron

SEC Form 4 filed by Chief Financial Officer Sandercock Brett

SEC Form 4 filed by Farrell Michael J.

SEC Form 4 filed by Sandercock Brett

SEC Form 4 filed by Farrell Peter C

Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)

Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)

Chief Financial Officer Sandercock Brett sold $254,300 worth of ResMed Common Stock (1,000 units at $254.30), decreasing direct ownership by 1% to 84,495 units (SEC Form 4)

Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,366,436 worth of ResMed Common Stock (4,991 units at $273.78) (SEC Form 4)

Director Farrell Peter C sold $502,620 worth of ResMed Common Stock (2,000 units at $251.31), decreasing direct ownership by 3% to 64,773 units (SEC Form 4)

Global General Counsel Rider Michael J sold $13,000 worth of ResMed Common Stock (50 units at $260.00), decreasing direct ownership by 0.51% to 9,691 units (SEC Form 4)

Chief Financial Officer Sandercock Brett sold $257,030 worth of ResMed Common Stock (1,000 units at $257.03), decreasing direct ownership by 1% to 85,495 units (SEC Form 4)

Director Farrell Peter C sold $497,660 worth of ResMed Common Stock (2,000 units at $248.83), decreasing direct ownership by 3% to 66,773 units (SEC Form 4)

Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,240,065 worth of ResMed Common Stock (4,991 units at $248.46) (SEC Form 4)

Chief Financial Officer Sandercock Brett sold $241,750 worth of ResMed Common Stock (1,000 units at $241.75), decreasing direct ownership by 1% to 86,495 units (SEC Form 4)

Global General Counsel Rider Michael J sold $12,088 worth of ResMed Common Stock (50 units at $241.75), decreasing direct ownership by 0.51% to 9,741 units (SEC Form 4)

Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,254,796 worth of ResMed Common Stock (4,991 units at $251.41) (SEC Form 4)

Director Farrell Peter C sold $502,940 worth of ResMed Common Stock (2,000 units at $251.47), decreasing direct ownership by 3% to 68,773 units (SEC Form 4)

Global General Counsel Rider Michael J sold $12,208 worth of ResMed Common Stock (50 units at $244.16), decreasing direct ownership by 0.51% to 9,791 units (SEC Form 4)

Chief Financial Officer Sandercock Brett sold $244,160 worth of ResMed Common Stock (1,000 units at $244.16), decreasing direct ownership by 1% to 87,495 units (SEC Form 4)

SEC Form 4 filed by Chairman and CEO Farrell Michael J.

SEC Form 4 filed by Director Farrell Peter C

Director De Witte Jan sold $524,025 worth of ReMed Common Stock (2,055 units at $255.00), decreasing direct ownership by 33% to 4,261 units (SEC Form 4)

SEC Form 4 filed by Director Mowad-Nassar Nicole

Chief Product Officer Leong Justin was granted 1,848 units of ReMed Common Stock, increasing direct ownership by 7% to 29,028 units (SEC Form 4)

Director Hernandez John was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 27% to 5,118 units (SEC Form 4)

Director Mowad-Nassar Nicole was granted 536 units of ResMed Common Stock, increasing direct ownership by 222% to 777 units (SEC Form 4)

Director Tan Desney was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 22% to 6,002 units (SEC Form 4)

Director Gill Harjit was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 11% to 10,940 units (SEC Form 4)

Director Drexler Karen was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 11% to 10,602 units (SEC Form 4)

Director Burt Carol was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 99% to 2,156 units (SEC Form 4)

Director Taylor Ronald R was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 5% to 24,771 units (SEC Form 4)

Chief Financial Officer Sandercock Brett was granted 2,710 units of ResMed Common Stock, increasing direct ownership by 3% to 88,495 units (SEC Form 4)

Chairman and CEO Farrell Michael J. was granted 13,551 units of ResMed Common Stock and covered exercise/tax liability with 7,297 units of ResMed Common Stock, increasing direct ownership by 1% to 466,223 units (SEC Form 4)

Director Delorefice Christopher was granted 1,073 units of ResMed Common Stock, increasing direct ownership by 79% to 2,423 units (SEC Form 4)

Director Farrell Peter C was granted 536 units of ResMed Common Stock, increasing direct ownership by 0.76% to 70,773 units (SEC Form 4)

Director De Witte Jan was granted 1,073 units of ReMed Common Stock, increasing direct ownership by 20% to 6,316 units (SEC Form 4)

SEC Form 4 filed by Director Sulpizio Richard

Director Farrell Peter C exercised 11,442 units of ResMed Common Stock at a strike of $101.64 and covered exercise/tax liability with 7,314 units of ResMed Common Stock, increasing direct ownership by 6% to 70,238 units (SEC Form 4)

Director Gill Harjit covered exercise/tax liability with 38 units of ResMed Common Stock, decreasing direct ownership by 0.39% to 9,867 units (SEC Form 4)

Director Farrell Peter C covered exercise/tax liability with 163 units of ResMed Common Stock and sold $504,100 worth of ResMed Common Stock (2,000 units at $252.05), decreasing direct ownership by 3% to 66,110 units (SEC Form 4)

Chairman and CEO Farrell Michael J. covered exercise/tax liability with 7,897 units of ResMed Common Stock, decreasing direct ownership by 2% to 459,969 units (SEC Form 4)

Director De Witte Jan sold $121,872 worth of ReMed Common Stock (487 units at $250.25) and covered exercise/tax liability with 76 units of ReMed Common Stock, decreasing direct ownership by 10% to 5,242 units (SEC Form 4)

Global General Counsel Rider Michael J covered exercise/tax liability with 1,525 units of ResMed Common Stock, decreasing direct ownership by 13% to 9,841 units (SEC Form 4)

Chairman and CEO Farrell Michael J. exercised 8,011 units of ResMed Common Stock at a strike of $101.64 and sold $2,000,773 worth of ResMed Common Stock (8,011 units at $249.75) (SEC Form 4)

Chief Financial Officer Sandercock Brett exercised 2,000 units of ResMed Common Stock at a strike of $101.64 and sold $742,620 worth of ResMed Common Stock (3,000 units at $247.54), decreasing direct ownership by 1% to 85,745 units (SEC Form 4)

Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,265,332 worth of ResMed Common Stock (8,009 units at $282.85) (SEC Form 4)

Chief Financial Officer Sandercock Brett exercised 2,000 units of ResMed Common Stock at a strike of $101.64 and sold $823,080 worth of ResMed Common Stock (3,000 units at $274.36), decreasing direct ownership by 1% to 86,745 units (SEC Form 4)

Global General Counsel Rider Michael J sold $27,436 worth of ResMed Common Stock (100 units at $274.36), decreasing direct ownership by 0.88% to 11,327 units (SEC Form 4)

Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,227,590 worth of ResMed Common Stock (8,009 units at $278.14) (SEC Form 4)

Director Mowad-Nassar Nicole was granted 241 units of ResMed Common Stock (SEC Form 4)

Chief Financial Officer Sandercock Brett exercised 2,000 units of ResMed Common Stock at a strike of $101.64 and sold $812,310 worth of ResMed Common Stock (3,000 units at $270.77), decreasing direct ownership by 1% to 87,745 units (SEC Form 4)

SEC Form 3 filed by new insider Mowad-Nassar Nicole

Chief Product Officer Leong Justin was granted 5,462 units of ReMed Common Stock, increasing direct ownership by 25% to 27,180 units (SEC Form 4)

Chief Financial Officer Sandercock Brett was granted 5,462 units of ResMed Common Stock, increasing direct ownership by 7% to 88,745 units (SEC Form 4)

Chief Executive Officer Farrell Michael J. was granted 12,289 units of ResMed Common Stock, increasing direct ownership by 3% to 467,792 units (SEC Form 4)

Director Hernandez John exercised 2,575 units of ResMed Common Stock at a strike of $148.90 and sold $739,289 worth of ResMed Common Stock (2,575 units at $287.10) (SEC Form 4)

Global General Counsel Rider Michael J was granted 2,941 units of ResMed Common Stock, increasing direct ownership by 35% to 11,427 units (SEC Form 4)